一種新型支架叫做Genous生物工程R支架，是以天然愈合途徑為基礎，對抗血栓形成并將血管狹窄降低至最小。該支架已經獲得了CE標志。

這種Genous支架的開發商是香港的OrbusNeich公司，該公司已經被挑選為Frost & Sullivan (Palo Alto, CA, USA)2005年技術創新獎的獲得者。每年，這項大獎授予那些開展新研究并導致創新的公司，這些研究已經或者即將對產業帶來顯著的貢獻。

Genous支架能夠以快速和可控制的方式促進組織愈合，而不是抑制愈合，包括內皮細胞覆蓋，強大的抗增殖藥物釋放支架。一項正在進行的臨床研究叫做HEALING II(健康內皮細胞加速排列抑制新血管內皮生長)，其初步研究結果的分析顯示，接受該支架的患者疾病的臨床轉歸較好。一項HEALING III多因素臨床研究不久即將開始，評估Genous的Statin治療與無覆蓋金屬支架的療效。

“Genous不是一種藥物釋放支架，沒有聚合體或者藥物。 ” 銷售與市場部副總裁David Camp指出。“這種支架使用抗體進行覆蓋，能夠捕獲患者自身循環中內皮細胞的祖細胞。這樣不僅能夠將再狹窄的可能降至最小，而且提供了對抗血栓的即時保護。”

OrbusNeich為全球60多個國家提供血管疾病的醫療設備。
 
Stent Promotes Tissue Healing
 
A new stent called the Genous bio-engineered R stent is based on a natural healing approach to protect against thrombus and to minimize stenosis. The stent has received the CE Mark.

The developer of the Genous stent, OrbusNeich (Hong Kong) has been selected as the recipient of a 2005 Technology Innovation Award from Frost & Sullivan (Palo Alto, CA, USA). Each year, this award is given to a company that has carried out new research resulting in innovations that have, or will, bring significant contributions to industry.

Genous stents promote tissue healing to occur in a rapid and controlled manner at the stent injury, rather than inhibiting healing, including endothelial coverage, with potent antiproliferative drug-eluting stents. An analysis of interim results of an ongoing clinical study called HEALING II (healthy endothelial accelerated lining inhibits neointimal growth) show that the patients who received the stent and were also on statins had better clinical outcomes. A HEALING III multifactorial clinical study will begin soon to assess the effect of statin therapy with Genous vs bare metal stents.

“Genous is not a drug-eluting stent, there is no polymer or drug,” said David Camp, vice president, sales and marketing. “The stent is coated with an antibody that captures a patient’s own circulating endothelial progenitor cells. This not only minimizes restenosis but also provides immediate protection against thrombus.”

OrbusNeich supplies medical devices for vascular diseases in more than 60 countries around the world.